April W. Armstrong, MD, MPH begins this session describing an overall treatment approach for psoriasis, which begins with determining if there is presence of psoriatic arthritis. With this in mind, Dr Armstrong proceeds to review the therapy options available for psoriasis and psoriatic arthritis, from adjunctive therapies (corticosteroids), conventional synthetic DMARDs (methotrexate, cyclosporine), biologic DMARDs, and targeted synthetic DMARDs (PDE4 inhibitors). When choosing a biologic, Dr Armstrong describes that each has a different efficacy profile for psoriatic arthritis and psoriasis and other considerations such as comorbid diseases and location of psoriatic arthritis (peripheral and/or axial) also impact selection choice. Bimekizumab is the newest FDA-approved biologic for treatment of plaque psoriasis and clinical trials indicate its efficacy for psoriatic arthritis as well. Dr Armstrong describes how IL-17 or IL-23 inhibitors are preferred over TNF blockers. Additionally, she discussed data on efficacy of other therapies including apremilast and deucravacitinib.